Allogene Therapeutics, Inc.ALLONASDAQ
LOADING
|||
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | -22.39% |
| Q2 2025 | -20.01% |
| Q1 2025 | 11.63% |
| Q4 2024 | 0.58% |
| Q3 2024 | -11.20% |
| Q2 2024 | -3.64% |
| Q1 2024 | -4.39% |
| Q4 2023 | 18.89% |
| Q3 2023 | -25.89% |
| Q2 2023 | -22.68% |
| Q1 2023 | 6.39% |
| Q4 2022 | 18.51% |
| Q3 2022 | 11.32% |
| Q2 2022 | -4.96% |
| Q1 2022 | 11.44% |
| Q4 2021 | -8.07% |
| Q3 2021 | 12.30% |
| Q2 2021 | -5.24% |
| Q1 2021 | 5.66% |
| Q4 2020 | 1.57% |
| Q3 2020 | 8.72% |
| Q2 2020 | 12.50% |
| Q1 2020 | -14.83% |
| Q4 2019 | 23.42% |
| Q3 2019 | 25.87% |
| Q2 2019 | 35.77% |
| Q1 2019 | 26.48% |
| Q4 2018 | 70.23% |
| Q3 2018 | -91.13% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |
| Q4 2017 | 0.00% |